Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Agilon Health (AGL) over the last 5 years, with FY2024 value amounting to $188.2 million.

  • Agilon Health's Cash & Equivalents rose 1587.66% to $171.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.7 million, marking a year-over-year increase of 1587.66%. This contributed to the annual value of $188.2 million for FY2024, which is 7498.47% up from last year.
  • According to the latest figures from FY2024, Agilon Health's Cash & Equivalents is $188.2 million, which was up 7498.47% from $107.6 million recorded in FY2023.
  • Agilon Health's Cash & Equivalents' 5-year high stood at $1.0 billion during FY2021, with a 5-year trough of $106.8 million in FY2020.
  • For the 5-year period, Agilon Health's Cash & Equivalents averaged around $381.6 million, with its median value being $188.2 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 87386.49% in 2021, then plummeted by 7688.17% in 2023.
  • Annual analysis of 5 years shows Agilon Health's Cash & Equivalents stood at $106.8 million in 2020, then surged by 873.86% to $1.0 billion in 2021, then plummeted by 55.26% to $465.3 million in 2022, then plummeted by 76.88% to $107.6 million in 2023, then skyrocketed by 74.98% to $188.2 million in 2024.
  • Its last three reported values are $188.2 million in FY2024, $107.6 million for FY2023, and $465.3 million during FY2022.